Henoch-Schönlein Purpura (IgA Vasculitis): Comprehensive Overview
Definition and Nomenclature
IgA vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, is an immune complex-mediated small-vessel vasculitis characterized by IgA1-dominant immune deposits affecting small vessels throughout the body 1. The disease was renamed from Henoch-Schönlein purpura to IgAV in the 2012 Chapel Hill Consensus Conference nomenclature, reflecting the understanding that abnormal IgA deposition within vessel walls represents the defining pathophysiological feature 1.
The historical context is important: Johann Lukas Schönlein first described the clinical association of purpura and arthritis in 1837, and Eduard Henoch later added gastrointestinal and renal manifestations in 1874 2.
Pathophysiology
The disease mechanism centers on circulating abnormally glycosylated IgA1 and IgA1-anti-IgA1 IgG immune complexes that deposit in small vessel walls 1. These immune complexes activate complement (particularly C3) and trigger neutrophil infiltration, leading to vascular inflammation and tissue damage 1, 3.
Key pathophysiological features include:
- Galactose-deficient IgA1 complexes that deposit in vessel walls
- Neutrophil activation via IgA Fc receptor (FcαRI/CD89), causing migration and tissue damage
- Complement activation with C3 deposition alongside IgA
- Endocapillary hypercellularity with prominent neutrophilic infiltration 1
Clinical Manifestations
Cutaneous Involvement
Palpable purpura is the hallmark and mandatory criterion for classification, typically predominating on the lower extremities 1. The skin lesions may also present as maculopapular or papular rash, and can extend above the waistline in more severe cases 1.
Gastrointestinal Involvement
Abdominal pain is very common, occurring in 37-65% of adult cases 1, 4. Severe gastrointestinal involvement includes:
- Massive gastrointestinal bleeding
- Intussusception
- Intestinal infarction
- Intestinal perforation
These severe manifestations are potentially life-threatening and require urgent management 1.
Renal Involvement (IgAV-Nephritis)
Kidney involvement should be suspected with haematuria, proteinuria, or reduced eGFR 1. Severe presentations include:
- Nephrotic syndrome (proteinuria with edema and hypoalbuminemia)
- Rapidly progressive glomerulonephritis (RPGN) with >50% eGFR decline over ≤3 months
Critical prognostic factors for progression to kidney failure:
- eGFR <60 ml/min/1.73 m² at presentation
- Proteinuria >0.5 g/day (or >0.5 g/g creatinine ratio)
- Male sex, Black ethnicity, diabetes 1
Histologically, IgAV-nephritis shows more prominent endocapillary hypercellularity (particularly neutrophilic), more frequent extracapillary proliferation (crescents), and more extensive capillary-wall IgA deposition compared to isolated IgA nephropathy 1.
Joint Involvement
Arthralgia and arthritis commonly affect large joints, particularly knees and ankles.
Diagnostic Approach
Clinical Diagnosis
The diagnosis relies on the combination of clinical, laboratory, and histological findings 1. Evidence of predominant IgA tissue deposits with compatible histology (leukocytoclastic vasculitis or mesangioproliferative glomerulonephritis) in a patient with suggestive clinical presentation strongly supports the diagnosis 1.
Important caveat: The absence of IgA deposits does not exclude the diagnosis, as direct immunofluorescence can be variable in adults 5.
Classification Criteria
The EULAR/PRINTO/PReS Ankara 2008 criteria can be applied to classify adult-onset IgAV 1. These require:
- Mandatory: Palpable purpura (typically lower limb predominant)
- Plus one or more of:
- Abdominal pain
- Kidney involvement (haematuria/proteinuria)
- Arthritis or arthralgia
- Histopathological evidence of IgA deposition
Critical distinction: These are classification criteria for research studies, not diagnostic criteria for clinical practice 1.
Trigger Identification
At diagnosis, search for potential triggers 1:
- Acute infections (particularly upper respiratory tract infections)
- Recently introduced drugs or vaccines
- Chronic infections (chronic viral hepatitis, oral/dental disease)
- Underlying malignancies (solid or hematological)
- Chronic liver disease
- IgA monoclonal gammopathies
The disease shows seasonal variation with twice the incidence during fall and winter, suggesting environmental triggers 3.
Kidney Biopsy Indications
A kidney biopsy is indicated when 1:
- Diagnostic uncertainty regarding IgAV-nephritis in systemic vasculitis
- Rapid worsening of kidney function (>30% eGFR decline in 1-2 weeks)
- Persistent proteinuria >0.5 g/g for 2-4 weeks despite treatment
Histology should be classified using the MEST-C score (Mesangial hypercellularity, Endocapillary hypercellularity, Segmental glomerulosclerosis, Tubular atrophy/interstitial fibrosis, Crescents) 1.
Adult vs. Pediatric Disease
Adult-onset IgAV is fundamentally more severe than pediatric disease 6, 7, 5:
- Higher rates of renal involvement (up to 80% in adults vs. 20-50% in children)
- Greater risk of progression to end-stage renal disease (10.8-21.3% in adults) 1
- More severe gastrointestinal complications
- Higher long-term morbidity and mortality
- More extensive glomerulosclerosis and interstitial fibrosis 1
Treatment Algorithm
Mild Disease (Skin/Joint Involvement Only)
Symptomatic treatment is sufficient 1:
- Analgesia for pain
- Rest and supportive care
- Alternative options: Colchicine or dapsone for persistent skin lesions 1
Moderate Disease
For persistent proteinuria or mild kidney dysfunction:
- Renin-angiotensin-aldosterone system (RAAS) blockade with ACE inhibitor or ARB 1, 8
- SGLT2 inhibitors for patients at risk of progressive kidney function loss 8
- Monitor blood pressure, eGFR, and proteinuria at 3 and 6 months 1
- Consider kidney biopsy if disease progresses 1
Severe Disease
For rapidly progressive glomerulonephritis, nephrotic syndrome, or severe gastrointestinal involvement 1:
Primary therapy:
- Prednisone 1 mg/kg/day (maximum 60 mg/day) 1
- Taper over 6 months
- ± Intravenous methylprednisolone pulses for severe presentations
- ± Cyclophosphamide for rapidly progressive disease 1, 8
- ± Plasmapheresis in select cases 1
Rapidly progressive IgAV-nephritis specifically:
- Treat according to KDIGO 2024 ANCA-Associated Vasculitis guidelines
- Cyclophosphamide plus systemic glucocorticoids 8
- Note: Insufficient evidence for rituximab in rapidly progressive IgAV 8
Refractory or Relapsing Disease
Consider alternative immunosuppression 1:
- B-cell depletion therapy (rituximab)
- Mycophenolate mofetil (MMF)
Chronic Kidney Disease Management
For established CKD from IgAV-nephritis 1:
- RAAS inhibitors and/or SGLT2 inhibitors
- Sodium-restricted diet
- Blood pressure control (target <130/80 mmHg)
- Cardiovascular risk factor management
Emerging therapies for IgA-mediated disease:
- Sparsentan (dual endothelin-1 and angiotensin II receptor blocker) - replaces rather than adds to RASi 8
- Complement inhibitors (under investigation)
- Mucosal immune system targeting (under investigation) 7
Monitoring and Prognosis
Surveillance Strategy
Continuous monitoring of renal parameters is essential, even after apparent remission 9, 5:
- Urinalysis and proteinuria quantification
- Serum creatinine and eGFR
- Blood pressure monitoring
- Duration: Several months to years, as nephritis can appear subclinically weeks after initial presentation 9
Prognostic Factors
Poor renal outcomes associated with 1:
- Proteinuria >1 g/day
- eGFR <60 ml/min/1.73 m² at presentation
- eGFR <30 ml/min/1.73 m² (very high risk)
- Glomerular sclerosis >10%
- Moderate-to-severe interstitial fibrosis and tubular atrophy
- Glomerular necrosis >10%
Mortality risk factors 1:
- Advanced age
- Purpura above the waistline
- Pre-existing heart failure
Kidney failure outcomes:
- 10.8-21.3% of adults with IgAV-nephritis develop kidney failure 1
- 92.6% of those who develop kidney failure do so within 10 years 1
- 48.1% develop kidney failure within 3 years of diagnosis 1
Critical Clinical Pitfalls
Common diagnostic errors:
- Misattribution to drug reactions when purpura follows antibiotic use 10
- Confusion with diverticulitis when abdominal pain predominates 10
- Failure to recognize adult disease due to focus on pediatric criteria 5
- Missing delayed renal involvement by discontinuing monitoring too early 9
Management errors:
- Underestimating severity in adults compared to children
- Delaying immunosuppression in rapidly progressive disease
- Failing to screen for underlying malignancy or chronic infection in adults
- Not obtaining kidney biopsy when indicated for prognostic information
Special Populations
Pregnancy
Women of childbearing potential require preconception counseling 8:
- Discontinue RASi, SGLT2i, and sparsentan before conception
- Optimize blood pressure with pregnancy-compatible medications
- Systemic glucocorticoids may be used during pregnancy
- Consider trial of immunosuppression before conception in high-risk patients
The disease course in adults is fundamentally different from children, requiring heightened vigilance for severe complications, particularly renal and gastrointestinal involvement, with treatment intensity matched to disease severity and close long-term monitoring for delayed renal manifestations.